2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma

Affiliations

• ¹ Department of Medical Oncology and Hematology, University of Manitoba, Winnipeg, MB, Canada.
• ² Division of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada.
• ³ Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
• ⁴ Department of Urology, CHU de Bordeaux, France.
• ⁵ Section of Urology, Department of Surgery, University of Calgary, Calgary, AB, Canada.
• ⁶ The Ottawa Hospital Research Institute, Division of Medical Oncology, University of Ottawa, Ottawa, ON, Canada.
• ⁷ The Ottawa Hospital Research Institute, Division of Urology, Department of Surgery, University of Ottawa, Ottawa, ON, Canada.
• ⁸ Chu de Québec, Université Laval, Quebec, QC, Canada.
• ⁹ Division of Urology, Department of Surgery, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.
• ¹⁰ Department of Oncology, Arthur JE Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB, Canada.
• ¹¹ Division of Urology, Western University, London, ON, Canada.
• ¹² Department of Medical Oncology, BC Cancer-Vancouver Center, Vancouver, BC, Canada.
• ¹³ Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
• ¹⁴ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
• ¹⁵ Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
• ¹⁶ Department of Medicine, Medical Oncology Division, BC Cancer-Vancouver Centre, University of British Columbia, Vancouver, BC, Canada.
• ¹⁷ Division of Urology, McGill University Health Centre, Montreal, QC, Canada.
• ¹⁸ Division of Medical Oncology, Dalhousie University, Halifax, NS, Canada.
• ¹⁹ Division of Urology, Centre Hospitalier Universitaire de Sherbrooke and Université de Sherbrooke Cancer Research Institute, Sherbrooke, QC, Canada.